Abstract: The invention concerns a pharmaceutical preparation which contains one or several galacturonides as the active substance with a degree of polymerization of .gtoreq.2 and a degree of esterification of <20% optionally together with common pharmaceutical carriers, diluents, auxiliary substances and fillers as well as the use of this preparation to block the attachment of germs to mammalian cells.

Abstract: A process is described for the production of a readily water-soluble fructan as well as a well-tolerated renal diagnostic agent containing such a fructan. In the process an aqueous fructan extract obtained from parts of plants is ultrafiltered over a first membrane which retains carbohydrates and proteins with a higher molecular weight but which allows passage of fructan and the filtrate obtained in this way is then filtered in a second ultrafiltration through a membrane which retains fructan but which allows passage of salts and low-molecular substances such as monosaccharides and oligosaccharides. The fructan obtained in this way is used as a renal diagnostic agent together with physiologically tolerated buffer substances at an osmolality which corresponds to that of blood and which has a pH of 5.0 to 7.0.

Abstract: A metabolizable blood plasma substitute is described which contains a starch ester with a molecular weight (Mw) of>20000 Daltons and a molar substitution of 0.1 to 1.5 as a colloidal component. The starch ester is for example acetyl starch with a molecular weight (Mw) of 200000 to 230000 Daltons and a molar substitution of 0.3 to 0.5.

Abstract: A pharmaceutical composition is described as well as the use of a starch ester for the production of such a pharmaceutical composition for peritoneal dialysis (CAPD) in particular for continuous ambulatory peritoneal dialysis. Starch esters which are particularly suitable are e.g. acetyl starch with a molecular weight (Mw) of 100000 to 200000 Daltons and a molar substitution of 0.3 to 0.5. Using the compositions according to the invention it is possible to carry out peritoneal dialysis without damaging the peritoneal epithelium. In addition it is not stored in the organs.

Abstract: A process is described for the production of starch degradation products with a narrow molecular weight distribution which is characterized in that a native starch, a starch derivative, a partially hydrolysed starch or a partially hydrolysed starch derivative in aqueous dispersion, suspension or solution is subjected to the action of ultrasound. Starch degradation products with a narrow molecular weight distribution can be obtained in high yields using this process.

Abstract: There are described novel compounds of the general formula ##STR1## in which R in position 3 or 4 is hydrogen, methyl, chlorine or bromine and R.sup.2 is C.sub.1 -C.sub.10 -alkyl, C.sub.3 -C.sub.7 -cycloalkyl or benzyl, and the pharmaceutically acceptable addition salts thereof with weak organic acids as well as a process for the preparation thereof.The compounds of formula (I) are inhibitors of thromboxane synthetase.

Abstract: New aryloxy-alkylamine derivatives of the general formula I ##STR1## in which A signifies a benzene or thiophene ring, R and R.sub.1, independently of one another, each hydrogen, alkyl, halogen, CF.sub.3 or alkoxy, R.sub.2 alkyl, cycloalkyl, alkenyl, alkynyl, alkaryl or saturated or unsaturated aliphatic or aromatic acyl, R.sub.3 and R.sub.4 in each case hydrogen, alkyl, alkenyl, alkynyl or cycloalkyl with, in each case, up to 8 C-atoms, whereby R.sub.3 and R.sub.4 can be the same or different but are not simultaneously hydrogen or R.sub.3 and R.sub.4, together with the nitrogen atom connecting them, form a 5- to 7-membered saturated ring or a saturated heterocyclic ring which can possibly contain an oxygen or nitrogen atom as a further heteroatom in the ring, whereby an additional nitrogen atom can be substituted by an alkyl radical with up to 3 C-atoms, and their acid-addition salts possess interesting pharmaceutical properties and are especially suitable as anti-arrhythmics.

Abstract: 1-(3-(2-hydroxy-3-alkylaminopropoxy)-2-thienyl)-3-phenyl-1-propanones represented by formula (I) ##STR1## wherein R.sub.1 and R.sub.2 each represent a lower alkyl group, and a process for the preparation of the same. The compounds of the present invention are useful in the treatment of cardiac arrhythmias.

Abstract: The present invention provides a process for the preparation of a plasma based on starch by the hydrolytic decomposition of an amylopectin-rich starch to a definite molecular weight and partial etherification to a definite substitution before or after the hydrolysis, wherein the hydrolytic decomposition is carried out at least partly with .alpha.-amylase, .beta.-amylase or pullulanase.

Abstract: The invention relates to new therapeutically valuable derivatives of 2-(2-thienyl)-imidazo[4,5-b]pyridines of the general formula ##STR1## in which R is methyl or ethyl, R.sub.1 is hydrogen or methyl and R.sub.2 is methylthio, methylsulfinyl oder methoxy, and their pharmaceutically acceptable acid addition salts, which compounds possess pharmacological properties, especially a positively inotropic activity on the heart.

Abstract: The disclosure is directed to new derivatives of thiophene-2-carboxylic acid and the pharmaceutically acceptable acid or base addition salts thereof as well as to the process for the preparation thereof. The compounds of the invention have the structural formula ##STR1## in which R in position 3 or 4 of the thiophene nucleus is hydrogen, methyl, chlorine or bromine and R.sub.1 is hydrogen or C.sub.1 -C.sub.4 -alkyl. The compounds have a remarkably strong inhibitory effect on the thromboxane synthetase and are useful for the treatment of conditions such as inflammation, hypertension, thrombus, apoplexy, asthma, angina pectoris, ischemic heart diseases, ischemic conditions, migraine and vascular complications in connection with diabetes.

Abstract: The disclosure is directed to novel 1-[3-(2-hydroxy-3-alkylaminopropoxy)-2-thienyl]-3-phenyl-1-propanones and their salts. The compounds of the invention have the structural formula ##STR1## in which R and R.sub.1 are independently hydrogen or methyl and R.sub.2 is n-propyl, n-butyl, isobutyl or tert-butyl. The compounds have an outstanding antiarrhytmical activity already in low doses.

Abstract: A process for preparing hydroxyethyl starch suitable as a plasma extender by alkaline hydroxyethylation and neutralization wherein the hydroxyethyl starch is extracted with a solvent such as dimethylformamide to remove the salts formed on neutralization.